0.55Open0.79Pre Close65 Volume2.39K Open Interest10.00Strike Price2.49KTurnover157.04%IV16.63%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.31Extrinsic Value100Contract SizeAmericanOptions Type0.2776Delta0.2101Gamma35.36Leverage Ratio-0.0573Theta0.0003Rho9.82Eff Leverage0.0034Vega
Omeros Stock Discussion
how long will the hold off volume before reaching above 30
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet